| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/18/2000 | US6015712 Antisense modulation of FADD expression |
| 01/18/2000 | US6015578 Trapidil for use in the therapy of syndrome that may be influenced by immunomodulators |
| 01/18/2000 | US6015572 Glial cells with neurotropic factors for nerve damage |
| 01/18/2000 | US6015557 Tumor necrosis factor antagonists for the treatment of neurological disorders |
| 01/18/2000 | US6015555 Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| 01/18/2000 | CA2132954C Modified ciliary neurotrophic factors |
| 01/18/2000 | CA2118174C Galanthamine derivatives, a process for their preparation and their use as medicaments |
| 01/18/2000 | CA2003837C Fused heterocyclic derivatives of 1,2,3,4-tetrahydroacridine, a process for their preparation and their use as medicaments |
| 01/13/2000 | WO2000001851A1 Antisense oligonucleotides targeted to il-15 |
| 01/13/2000 | WO2000001821A2 Neurotransmission associated proteins |
| 01/13/2000 | WO2000001815A2 Neurotrophic factors |
| 01/13/2000 | WO2000001805A1 Cells and animals deficient in protein kinase c epsilon |
| 01/13/2000 | WO2000001699A1 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
| 01/13/2000 | WO2000001694A1 Paroxetine methanesulfonate |
| 01/13/2000 | WO2000001692A1 Salts of paroxetine |
| 01/13/2000 | WO2000001680A1 New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use |
| 01/13/2000 | WO2000001676A1 Potassium channel blocking agents |
| 01/13/2000 | WO2000001675A1 Novel benzimidazoles as corticotropin release factor antagonists |
| 01/13/2000 | WO2000001668A2 Naaladase inhibitors useful as pharmaceutical compounds and compositions |
| 01/13/2000 | WO2000001666A1 C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
| 01/13/2000 | WO2000001440A2 Methods for treating neurological injuries and disorders |
| 01/13/2000 | WO2000001415A2 Use of inhibitors of protein kinase c epsilon to treat pain |
| 01/13/2000 | WO2000001403A1 USE OF COMPOSITION COMPRISING AT LEAST ONE SUBSTANCE WITHIN THE GROUP GnRH-ANALOGUES FOR TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD) |
| 01/13/2000 | WO2000001389A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 01/13/2000 | WO2000001380A1 cyclo-oxygenase inhibitor |
| 01/13/2000 | WO2000001377A2 Nalmefene in combination with opioid analgesics |
| 01/13/2000 | WO2000001376A2 Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| 01/13/2000 | WO2000001375A2 Calcium channel blockers |
| 01/13/2000 | WO1999059617A3 Immunoregulator |
| 01/13/2000 | WO1999057241A3 Myelin basic protein peptides and uses thereof |
| 01/13/2000 | WO1999056770A3 Novel therapy for treatment of lysosomal storage disease |
| 01/13/2000 | WO1999046367A8 Methods of diagnosis and triage using cell activation measures |
| 01/13/2000 | WO1999018941A3 Ih-MODULATORS |
| 01/13/2000 | DE19830431A1 Sulfonylamino-carbonsäure-N-arylamide als Guanylatcyclase-Aktivatoren Sulfonylamino-carboxylic acid N-arylamides as guanylate cyclase activators |
| 01/13/2000 | DE19830201A1 Mittel mit antidepressiver Wirkung Agent with an antidepressant activity |
| 01/13/2000 | CA2658200A1 Naaladase inhibitors useful as pharmaceutical compounds and compositions |
| 01/13/2000 | CA2379524A1 Salts and bases of the 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opiod analgesics |
| 01/13/2000 | CA2336718A1 Methods for treating neurological injuries and disorders |
| 01/13/2000 | CA2336714A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 01/13/2000 | CA2336709A1 Use of inhibitors of protein kinase c epsilon to treat pain |
| 01/13/2000 | CA2336656A1 Use of composition comprising at least one substance within the group gnrh-analogues for treatment of obsessive-compulsive disorder (ocd) |
| 01/13/2000 | CA2336470A1 Salts of paroxetine |
| 01/13/2000 | CA2336419A1 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
| 01/13/2000 | CA2335779A1 Novel benzimidazoles as corticotropin release factor antagonists |
| 01/13/2000 | CA2332699A1 Antisense oligonucleotides targeted to il-15 |
| 01/13/2000 | CA2332309A1 Neurotransmission associated proteins |
| 01/12/2000 | EP0971033A2 Test and model for Alzheimer's disease |
| 01/12/2000 | EP0970957A1 Diaza-spiro[3,5] nonane derivatives |
| 01/12/2000 | EP0970955A1 Paroxetine methanesulfonate |
| 01/12/2000 | EP0970949A1 Acridine derivatives |
| 01/12/2000 | EP0970702A1 Brain activators |
| 01/12/2000 | EP0970695A1 Methods for increasing levels of acetylcholine |
| 01/12/2000 | EP0970379A1 Methods to identify beta-amyloid reducing agents |
| 01/12/2000 | EP0970372A1 Assay for disease related conformation of a protein |
| 01/12/2000 | EP0970223A1 Serine/threonine protein kinase |
| 01/12/2000 | EP0970213A2 Death domain containing receptor 5 |
| 01/12/2000 | EP0970211A1 Variants of ciliary neurotrophic factor with enhanced receptor selectivity and method for their selection |
| 01/12/2000 | EP0970203A2 Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans |
| 01/12/2000 | EP0970195A1 Fatty-acid amide hydrolase |
| 01/12/2000 | EP0970121A1 Peptide fragments of myelin basic protein, their pharmaceutical compositions and their use in treating multiple sclerosis |
| 01/12/2000 | EP0970112A2 Novel human cytokine/steroid receptor protein |
| 01/12/2000 | EP0970111A2 Secreted proteins and polynucleotides encoding them |
| 01/12/2000 | EP0970109A2 Secreted proteins and polynucleotides encoding them |
| 01/12/2000 | EP0970090A1 Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use |
| 01/12/2000 | EP0970083A1 7a-HETEROCYCLE-SUBSTITUTED HEXAHYDRO-1H-PYRROLIZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION |
| 01/12/2000 | EP0970082A2 Biazacyclic crf antagonists |
| 01/12/2000 | EP0970080A1 Imino-aza-anthracyclinone derivatives for the treatment of amyloidosis |
| 01/12/2000 | EP0970076A1 7-[(piperidin-1-yl)- propoxy]-chromen-4-one derivatives, their preparation and their pharmaceutical use |
| 01/12/2000 | EP0970054A1 1-(isoquinolin-1-yl)-4-(1-phenylmethyl)piperazines; dopamine receptor subtype specific ligands |
| 01/12/2000 | EP0970043A1 Compounds consisting in particular of effectors of the central nervous system receptors sensitive to excitatory amino acids, preparation and biological applications |
| 01/12/2000 | EP0970036A1 Aryl- and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity |
| 01/12/2000 | EP0969875A1 Adenoviral-vector-mediated gene transfer into medullary motor neurons |
| 01/12/2000 | EP0969874A1 Pharmaceutical compositions containing propanamine derivatives and cyclodextrin |
| 01/12/2000 | EP0969845A1 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders |
| 01/12/2000 | EP0969842A1 Pharmaceutical composition |
| 01/12/2000 | EP0969835A1 Use of central cannabinoid receptor antagonists for regulating appetence |
| 01/12/2000 | EP0969830A1 Drugs for memory enhancement |
| 01/12/2000 | EP0969823A2 Anti-epileptogenic agents |
| 01/12/2000 | EP0969817A1 Dosage forms having improved release properties |
| 01/12/2000 | EP0808307B1 Bicyclic isothiourea derivatives useful in therapy |
| 01/12/2000 | EP0781285B1 Fused indole and quinoxaline derivatives, their preparation and use as glutamate antagonists |
| 01/12/2000 | EP0781284B1 Indole-2,3-dione-3-oxime derivatives, their preparation and use |
| 01/12/2000 | EP0731698B1 Modafinil having defined particle size |
| 01/12/2000 | EP0640081B1 Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht4 antagonists |
| 01/12/2000 | EP0639079B1 Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| 01/12/2000 | CN1241193A Meningococcus vaccine comprising valence of BZ23 strain |
| 01/12/2000 | CN1241178A Novel compounds with analgesic effect |
| 01/12/2000 | CN1240788A Acridine derivatives |
| 01/12/2000 | CN1240646A Injectable composition of non-steroidal anti-inflammatory drugs |
| 01/12/2000 | CN1048247C Neuroprotective chroman compounds |
| 01/11/2000 | US6013814 Vitamin D analogues |
| 01/11/2000 | US6013809 Analgesics |
| 01/11/2000 | US6013796 Simplification, efficiency, nontoxic |
| 01/11/2000 | US6013781 Semaphorin gene family |
| 01/11/2000 | US6013675 Therapeutic substituted guanidines |
| 01/11/2000 | US6013674 Indenone amide derivatives, useful for for the inhibition of leukocyte adherence to endothelial cells; useful in the treatment of inflammatory diseases, as arthritis, asthama, psoriasis, respiratory distress syndrome, stroke and ulcer |
| 01/11/2000 | US6013672 Administering to an individual suffering from head, spinal cord trauma, stroke and epilepsy a therapeutically effective dose of a metabotropic glutamate receptor agonist |
| 01/11/2000 | US6013656 2-(arylalkenyl) azacycloalkane derivatives as ligands for sigma receptors |
| 01/11/2000 | US6013646 Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
| 01/11/2000 | US6013627 Organic compounds |